{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002711","form_type":"8-K","ticker":"NUTX","cik":"0001479681","company_name":"Nutex Health Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.182004+00:00","generated_at":"2026-06-18T14:56:48.383472+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nutex Health reports FY2022 revenue of $219.3M, net loss of $424.8M on $398.1M goodwill impairment","bullets":["Total revenue $219.3M for FY2022; Q4 revenue $53.7M; net loss attributable to Nutex $424.8M.","Adjusted EBITDA $12.5M for FY2022; Q4 adjusted EBITDA loss of $5.9M.","Net cash from operating activities $50.6M; cash and equivalents $34.3M at year-end.","Goodwill impairment of $398.1M; warrant/option valuation revision reduced impairment by $10.3M.","No Surprises Act reduced revenue by ~$29M in Q3 and $9.6M in H1 2022; company plans 19 new facilities by mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002711","json":"https://secwatch.observer/filing/0001558370-23-002711.json","markdown":"https://secwatch.observer/filing/0001558370-23-002711.md","text":"https://secwatch.observer/filing/0001558370-23-002711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479681/000155837023002711/0001558370-23-002711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479681/000155837023002711/nutx-20230302x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T14:56:48.383472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ff4193b6e7aa40b458146de141e978249fa3f08","claim":"Nutex Health Inc. reported the fiscal year ended December 31, 2022 results: revenue $219.3 million, net income Net loss attributable to Nutex Health Inc. of $424.8 million.","evidence_excerpt":"99.1 to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- ​ ​ NUTEX HEALTH Inc. reports fourth quarter and Full YEAR 2022 financial results ​ ● Total revenue of $219.3 million for the year ended 2022 ● Net cash from operating activities of $50.6 million for the YEAR ended 2022 ● Company expects to open 19 NEW facilities by mid-2025 ​ HOUSTON, TX −","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479681/000155837023002711/0001558370-23-002711-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$219.3 million"},{"label":"Net income","value":"Net loss attributable to Nutex Health Inc. of $424.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"40100a6356453ef7655412af7b0fecb00a013fb5","claim":"Nutex Health Inc. reported the three months ended December 31, 2022 results: revenue $53.7 million, net income Net loss attributable to Nutex Health of $14.7 million.","evidence_excerpt":"Financial Highlights for the Three Months Ended December 31, 2022: ● Total revenue of $53.7 million. ● Net loss attributable to Nutex Health of $14.7 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479681/000155837023002711/0001558370-23-002711-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$53.7 million"},{"label":"Net income","value":"Net loss attributable to Nutex Health of $14.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}